Seoul Asan Medical Center said it started prescribing the early Alzheimer's disease drug "Leqembi" (generic name lecanemab) ...

Bristol Myers Squibb acquires global rights to BioArctic’s Alzheimer’s antibody candidates BAN1503 and BAN2803 for up to $1.3 ...

China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...

Explaining its decision, the regulator said that while patients treated with Leqembi (lecanemab) experienced a reduction in disease progression compared to those given a placebo in the pivotal ...

finds itself at a critical juncture as it navigates the launch of its Alzheimer's treatment Leqembi (lecanemab) and manages a shifting pipeline landscape. With a market capitalization of $22 ...

From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol ...

The company invented Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been ...

Lecanemab (Leqembi) and donanemab (Kisunla) have both received FDA approval as amyloid-beta targeting therapies.⁷⁻⁸ Several ...

Leqembi, from Japan's Eisai and its U.S. partner ... Scrutiny of the new drug, known chemically as lecanemab, will likely mean most patients won’t start receiving it for months, as insurers ...